# EDGAR Filing Document

**Accession Number:** 0001896212
**File Stem:** 0001641172-25-023010
**Filing Date:** 2025-8
**Character Count:** 21627
**Document Hash:** 7dda2322a32bac9d9c49f6d28a679b65
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-023010.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001641172-25-023010

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**EFFECTIVENESS DATE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CDT Equity Inc.
- **CENTRAL INDEX KEY:** 0001896212
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 873272543
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289496
- **FILM NUMBER:** 251202983

**BUSINESS ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103
- **BUSINESS PHONE:** (646) 491 9132

**MAIL ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CONDUIT PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20230922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Murphy Canyon Acquisition Corp.
- **DATE OF NAME CHANGE:** 20211130

**As filed with the Securities and Exchange Commission on August 11, 2025**

**Registration No. 333-__________**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**CDT EQUITY INC.**

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **87-3272543** |
| **(State or other jurisdiction**<br> **of incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **4581 Tamiami Trail North, Suite 200**<br> **Naples, FL** | **34103** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**CDT Equity Inc. 2023 Amended and Restated Stock Incentive Plan**

**(Full title of the plan)**

**Andrew Regan**

**Chief Executive Officer**

**CDT Equity Inc.**

**4581 Tamiami Trail North, Suite 200**

**Naples, FL 34103**

**(Name and address of agent for service)**

**(646) 491-9132**

**(Telephone number, including area code, of agent for service)**

***Copies to:***

**Todd Mason, Esq.**

**Thompson Hine LLP**

**300 Madison Ave, 27th Floor**

**New York, NY 10017**

**(212) 344-5680**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

**EXPLANATORY NOTE**

Effective August 5, 2025, Conduit Pharmaceuticals Inc. changed its name to CDT Equity Inc. (the "Registrant").

On January 25, 2025, and May 19, 2025, the Registrant effected a 1-for-100 reverse stock split and a 1-for-15 reverse stock split of its issued and outstanding common stock, respectively (collectively, the "Reverse Stock Splits"). Unless otherwise indicated, all share numbers herein, including common stock registered hereunder and registered under prior registration statements, give effect to the Reverse Stock Splits.

This registration statement on Form S-8 registers an additional 2,000,000 shares of common stock of the Registrant that may be issuable under the CDT Equity Inc. Amended and Restated 2023 Stock Incentive Plan (as may be amended from time to time, the "2023 Plan" or the "Plan"), which was recently approved by the Registrant's Board of Directors on July 8, 2025, and by the Registrant's stockholders on August 5, 2025.

The Registrant previously registered (i) 7,665 shares of common stock available for issuance under the 2023 Plan on a registration statement on Form S-8, filed by the Registrant on [December 1, 2023](https://www.sec.gov/Archives/edgar/data/1896212/000149315223043433/forms-8.htm), File No. 333-275860, (ii) 2,460 shares of common stock available for issuance under the 2023 Plan pursuant to the Plan's evergreen provision effective January 1, 2024, on a registration statement on Form S-8, filed by the Registrant on [January 10, 2024](https://www.sec.gov/Archives/edgar/data/1896212/000149315225005249/forms-8.htm), File No. 333-276461, and (iii) 4,616 additional shares of common stock for issuance under the 2023 Plan pursuant to the Plan's evergreen provision effective January 1, 2025, on a registration statement on Form S-8, filed by the Registrant on [February 6, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000149315225005249/forms-8.htm), File No. 333-284741 (such registration statements on Form S-8, the "Prior Registration Statements"). In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference in this registration statement. Only those items of Form S-8 containing new information not contained in the in the Prior Registration Statements are presented herein.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

As permitted by the rules of the U.S. Securities and Exchange Commission (the "SEC"), this registration statement omits the information specified in Part I of Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the SEC are incorporated by reference into this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1896212/000164117225001246/form10-k.htm) for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025.

(b) The
 Registrant's Quarterly Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1896212/000164117225010405/form10-q.htm) for the period ended March 31, 2025, filed with the SEC on May 15, 2025.

(c) The
 Registrant's Current Reports on Form 8-K (other than any portions thereof deemed furnished and not filed), filed with the SEC
 on [January 14, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000149315225002176/form8-k.htm) , [January 23, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000149315225003316/form8-k.htm) , [February 11, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000149315225005796/form8-k.htm) , [February 19, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000149315225007573/form8-k.htm) , [March 6, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000149315225009330/form8-k.htm) , [April 1, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225002147/form8-k.htm) (as amended on [April 2, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225002400/form8-ka.htm)), [April 4, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225002774/form8-k.htm) , [April 16, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225005036/form8-k.htm) , [April 25, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225006224/form8-k.htm) , [May 6, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225008854/form8-k.htm) , [May 16, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225011183/form8-k.htm) , [June 3, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225013468/form8-k.htm) , [June 9, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225014322/form8-k.htm) , and [August 8, 2025](https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/form8-k.htm) .

(d) The Registrant's definitive proxy statement on [Schedule 14A](https://www.sec.gov/Archives/edgar/data/1896212/000164117225018242/formdef14a.htm) , as filed with the SEC on July 8, 2025.

(e) The
 description of the Registrant's securities contained in the Registrant's registration statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1896212/000149315223033397/form8-a12b.htm) , filed with
 the SEC on September 22, 2023 (File No. 001-41245), as well as any additional amendments or reports filed for the purpose of updating
 such description.

(f) All
 other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of Securities Exchange
 Act of 1934, as amended (the "Exchange Act"), (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form
 8-K and exhibits furnished on such form that relate to such items) on or after the date of this registration statement and prior
 to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been
 sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be
 a part of this registration statement from the date of the filing of such reports and documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | [CDT Equity Inc. Amended and Restated 2023 Stock Incentive Plan (filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on August 8, 2025, and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/ex10-1.htm) |
| 4.2 | [Specimen Common Stock Certificate of CDT Equity Inc. (filed as Exhibit 4.8 to the Registrant's Amendment No. 3 to Registration Statement on Form S-4 (File No. 333-271903) filed on August 8, 2023, and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1896212/000149315223027178/ex4-8.htm) |
| 4.3 | [Form of Stock Option Agreement under the CDT Equity Inc. Amended and Restated 2023 Stock Incentive Plan (filed as Exhibit 10.17 to the Registrant's Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-17.htm) |
| 5.1\* | [Opinion of Thompson Hine LLP.](ex5-1.htm) |
| 23.1\* | [Consent of Marcum LLP, independent public accounting firm of CDT Equity Inc.](ex23-1.htm) |
| 23.2\* | [Consent of Thompson Hine LLP (included in Exhibit 5.1 hereto).](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](#a_001) |
| 107\* | [Filing Fee Table.](ex107.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Naples, State of Florida, on August 11, 2025.

---

| | |
|:---|:---|
| **CDT EQUITY INC.** | **CDT EQUITY INC.** |
| By: | */s/ Andrew Regan* |
| Name: | Andrew Regan |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Andrew Regan and/or James Bligh, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Andrew Regan* | Chief Executive Officer and Director | August 11, 2025 |
| Andrew Regan | (Principal Executive Officer) |  |
| */s/ James Bligh* | Chief Financial Officer and Director | August 11, 2025 |
| James Bligh | (Principal Financial Officer and Principal Accounting Officer) |  |
| */s/ Freda Lewis-Hall* | Director and Chairperson of the Board of Directors | August 11, 2025 |
| Freda Lewis-Hall |  |  |
| */s/ Chele Chiavacci Farley* | Director | August 11, 2025 |
| Chele Chiavacci Farley |  |  |
| */s/ Simon Fry* | Director | August 11, 2025 |
| Simon Fry |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

August 11, 2025

CDT Equity Inc.

4581 Tamiami Trail North, Suite 200

Naples, Florida 34103

**Re: Registration Statement on Form S-8 – CDT Equity Inc. Amended and Restated 2023 Stock Incentive Plan**

Ladies and Gentlemen:

CDT Equity Inc., a Delaware corporation (the "***Company***"), is filing with the U.S. Securities and Exchange Commission (the "***Commission***") a Registration Statement on Form S-8 (the "***Registration Statement***") for the registration, under the Securities Act of 1933, as amended (the "***Securities Act***"), of an additional 2,000,000 shares of common stock, par value $0.0001 per share, of the Company (the "***Common Stock***"), that are issuable at any time or from time to time under the CDT Equity Inc. Amended and Restated 2023 Stock Incentive Plan (as amended to date, the "***2023 Plan***").

Item 601 of Regulation S-K and the instructions to Form S-8 require that an opinion of counsel concerning the legality of the securities to be registered be filed as an exhibit to a Form S-8 registration statement if the securities are original issue shares. This opinion letter is provided in satisfaction of that requirement as it relates to the Registration Statement.

In rendering this opinion, we have examined the 2023 Plan, the Registration Statement, the certificate of incorporation of the Company, and the bylaws of the Company (each as amended and/or restated as of the date hereof) and such other records, instruments, and documents as we have deemed advisable in order to render this opinion letter. In such examination, we have assumed: (a) the genuineness of all signatures, (b) the legal capacity of all natural persons, (c) the authenticity of all documents, certificates, and instruments submitted to us as originals, (d) the conformity to original documents of all documents, certificates, and instruments submitted to us as certified, conformed, or photostatic copies, and (e) the authenticity of the originals of such latter documents. Our opinion set forth below is based on the text of the 2023 Plan as referenced in the Exhibits Index to the Registration Statement and is limited to the General Corporation Law of the State of Delaware (the "***DGCL***") as currently in effect, and we express no opinion as to the effect on the matters covered by this letter of the laws of any other jurisdiction.

As a result of the foregoing, and subject to the further limitations, qualifications, and assumptions set forth herein, we are of the opinion that, when issued pursuant to and in accordance with the terms of the 2023 Plan, the Common Stock that is the subject of the Registration Statement will be validly issued, fully paid, and non-assessable.

![](ex5-1_002.jpg)

![](ex5-1_003.jpg)

CDT Equity Inc.

August 11, 2025

In rendering the opinion above, we have assumed that: (a) the Company will have sufficient authorized and unissued shares of Common Stock at the time of each issuance of any of the shares of Common Stock under the 2023 Plan, (b) the shares of Common Stock issued pursuant to the 2023 Plan will be evidenced by appropriate certificates, duly executed and delivered, or the Company's Board of Directors has adopted or will adopt a resolution providing that all of the shares of Common Stock shall be uncertificated in accordance with Section 158 of the DGCL prior to their issuance, (c) the issuance of each share of Common Stock issued pursuant to the 2023 Plan will be duly noted in the Company's stock ledger upon its issuance, (d) the Company will receive consideration for each share of Common Stock issued pursuant to the 2023 Plan at least equal to the par value of such share of Common Stock, and in the amount required by the 2023 Plan (or the award agreement issued thereunder) and the Authorizing Resolutions (as defined below), (e) the resolutions authorizing the Company to issue the Common Stock pursuant to the 2023 Plan (the "***Authorizing Resolutions***") will be in full force and effect at all times at which the Common Stock is issued by the Company, and that the Company will take no action inconsistent with such Authorizing Resolutions, and (f) each award under the 2023 Plan will be approved by the Board of Directors of the Company or an authorized committee of the Board of Directors.

This opinion letter speaks only as of the date hereof. We expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law or fact that may occur after the date of this opinion letter that might affect the opinion expressed herein.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Thompson Hine LLP |
| Thompson Hine LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 28, 2025 relating to the financial statements appearing in the Annual Report on Form 10-K of CDT Equity, Inc. for the year ended December 31, 2024. We also consent to the reference to us under the heading "Experts" in such Registration Statement. Effective August 5, 2025, Conduit Pharmaceuticals Inc. changed its name to CDT Equity Inc.

/s/ Marcum LLP

Morristown, NJ

August 11, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8** (Form Type)

**CDT Equity Inc.** (Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Amount Registered** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, par value $0.0001 per share Other<sup>(1)</sup> | 2000000<sup>(2)</sup> | $1.87<sup>(1)</sup> | $3740000 | 0.00015310 | $572.60 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $3740000 |  | $572.60 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $– |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $572.60 |

---

(1) Calculated solely for purposes of this offering under
 Rules 457(c) and 457(h) of the Securities Act of 1933, as amended (the "Securities Act"), on the basis of the average
 of the high and low prices per share of Registrant's common stock on August 8, 2025 as reported by The Nasdaq Stock Market.

(2) Represents an additional 2,000,000 shares, not previously
 registered, of the Registrant's common stock that may be issued under the CDT Equity Inc. Amended and Restated 2023 Stock Incentive
 Plan (the "2023 Plan"), which was recently approved by the Registrant's Board of Directors on July 8, 2025, and
 by the Registrant's stockholders on August 5, 2025. Pursuant to Rule 416(a) promulgated under the Securities Act, this registration
 statement shall also cover any additional shares of Registrant's common stock that become issuable under the 2023 Plan by reason
 of any stock dividend, stock split, recapitalization, or other similar transaction effected without receipt of consideration that
 increases the number of outstanding shares of Registrant's common stock, as applicable.